7:33 PM
 | 
Sep 11, 2007
 |  BC Extra  |  Clinical News

Deja vu on Avandia

The Journal of the American Medical Association published two meta-analyses of the diabetes drugs Avandia rosiglitazone from GlaxoSmithKline (LSE:GSK; GSK) and Actos pioglitazone from Takeda (Tokyo:4502) and Eli Lilly (LLY), but neither added much that was new to the debate over the cardiovascular safety of the thiazolidinedione class of drugs.

Cleveland Clinic cardiologist Steven Nissen and colleagues looked at 19 trials enrolling 16,390 patients taking Actos. They concluded that the drug is associated with...

Read the full 374 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >